FULC Fulcrum Therapeutics, Inc.

NASDAQ
$3.77

Fulcrum Therapeutics, Inc. (FULC) is expected to report earnings on February 11, 2027, before the market open. The consensus earnings estimate is a loss of $0.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.8% since its last earnings release on November 12, 2026.

Fulcrum Therapeutics Reported In-line with Estimates
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · Before Open
Earnings Whisper
-
vs ($0.08)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $3.72

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and Phase 3 for the treatment of COVID-19. Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.